

Impact of oseltamivir treatment on influenza A and B dynamics in human volunteers

Kyla L. Hooker¹ and Vitaly V. Ganusov^{1,2,3*}

¹Genome Science and Technology, University of Tennessee, Knoxville, TN 37996, USA

²Department of Microbiology, University of Tennessee, Knoxville, TN 37996, USA

³Department of Mathematics, University of Tennessee, Knoxville, TN 37996, USA

*Corresponding author: vitaly.ganusov@gmail.com

November 13, 2020

Abstract

Influenza viruses infect millions of humans every year causing an estimated 400,000 deaths globally. Due to continuous virus evolution current vaccines provide only limited protection against the flu. Several antiviral drugs are available to treat influenza infection, and one of the most most commonly used drugs is oseltamivir (Tamiflu). While the mechanism of action of oseltamivir as a neuraminidase inhibitor is well understood, the impact of oseltamivir on influenza virus dynamics in humans has been controversial. Many clinical trials with oseltamivir have been done by pharmaceutical companies such as Roche but the results of these trials until recently have been reported as summary reports or papers. Typically, such reports included median virus shedding curves for placebo and drug-treated influenza virus infected volunteers often indicating high efficacy of the early treatment. However, median shedding curves may be not accurately representing drug impact in individual volunteers. Importantly, due to public pressure clinical trials data testing oseltamivir efficacy has been recently released in the form of redacted PDF documents. We digitized and re-analyzed experimental data on influenza virus shedding in human volunteers from three previously published trials: on influenza A (1 trial) or B viruses (2 trials). Given that not all volunteers exposed to influenza viruses actually start virus shedding we found that impact of oseltamivir on the virus shedding dynamics was dependent on i) selection of volunteers that were infected with the virus, and ii) the detection limit in the measurement assay; both of these details were not well articulated in the published studies. By assuming that any viral measurement is above the limit of detection we could match previously published data on median influenza A virus (flu A study) shedding but not on influenza B virus shedding (flu B study B) in human volunteers. Additional analyses confirmed that oseltamivir had an impact on the duration of shedding and overall shedding (defined as area under the curve) but this result was varied by the trial. Interestingly, treatment had no impact on the rates at which shedding increased or declined with time in individual volunteers. Additional analyses showed that oseltamivir impacted the kinetics of the start and end of viral shedding and in about 20-40% of volunteers treatment had no impact on viral shedding duration. Our results suggest an unusual impact of oseltamivir on influenza viruses shedding kinetics and caution about the use of published median data or data from a few individuals for inferences. Furthermore, we call for the need to publish raw data from critical clinical trials that can be then independently analyzed.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 **Abbreviations:** LOD: limit of detection, DOI: days of infection (also denoted as T); bid:
41 twice daily, od: once daily, AUC: area under the curve, LRT: likelihood ratio test.

42 Introduction

43 Influenza is a respiratory infection caused by different strains of the influenza virus. Influenza A
44 viruses originate from animals such as birds and pigs while influenza B viruses have no known animal
45 origin [1]. Disease, caused by influenza viruses, commonly known as the flu, typically affects the
46 upper respiratory system such as the sinus cavities, throat, and sometimes the lungs [2]. The virus
47 spreads from person to person via respiratory droplets when the infected individual coughs or sneezes
48 in close contact with uninfected individuals [3]. Symptoms include fever, fatigue, cough, sore throat,
49 and a runny nose. Most individuals recover from the flu [2]. However, individuals, usually with
50 underlying health conditions, can have serious and even deadly complications. Millions are infected
51 with influenza viruses globally, and 400,00-500,000 people die each year from complications following
52 influenza virus infections [1, 4]. The influenza virus has a high mutation rate resulting in new strains
53 (antigenic drift) that are not readily recognized by immunity of individuals previously experienced
54 influenza infection [2]. Occasionally, reassortment of viral genes may occur resulting in variants that
55 are markedly different from currently circulating strains (antigenic shift); such process often results
56 in a pandemic [5].

57 A common prevention is the yearly flu vaccine, but it is not very efficient with an estimated
58 efficacy of about 60% which varies with vaccination year and age of vaccinated individuals [6]. The
59 influenza virus has a high mutation rate allowing it to escape from vaccine-induced immunity [2].
60 Thus, new influenza vaccines need to be created annually. The creation of the annual influenza
61 vaccination takes into consideration both new strains and current strains of influenza viruses that
62 are circulating globally [1, 7].

63 Luckily there are several antiviral drugs such as oseltamivir, zanamivir, peramivir, and baloxavir
64 that can be used to either treat severely ill influenza-infected patients or household contacts of
65 individuals with confirmed influenza infection [8–10]. Efficacy of such drugs has been extensively
66 evaluated in clinical trials both including infected patients and volunteers that had been infected
67 with a known strain and dose of an influenza virus. In latter types of experiments treatment start
68 can be well defined relative to the infection initiation, and for oseltamivir the treatment appears
69 to impact virus dynamics and/or patient’s symptoms when the treatment is started only within 24
70 hours of the infection and/or onset of symptoms [2]. There are also other limitations of oseltamivir
71 including side effects and the appearance of drug resistant variants [2, 11].

72 While evidence of the efficacy of drugs against influenza infection such as oseltamivir has been
73 well documented from several clinical trials (e.g., [12, 13]) for a long time there has been very limited
74 publicly available data from such clinical trials. In particular, results of clinical trials have been
75 presented as median viral shedding curves or symptoms for placebo and drug-treated volunteers, and
76 side effects of the treatments were barely discussed. Interestingly, initial reviews of such clinical trials
77 data recommended oseltamivir use for treating influenza infection [14]; many governments stockpiled
78 oseltamivir for emergency use in case of a new pandemic virus [15]. However, concerns of whether
79 the clinical trials data were accurately represented in original publications were raised resulted in
80 some reports of the clinical trials with oseltamivir to be publicly released. Interestingly, reanalysis of
81 these and other data reduced the initial enthusiasm to recommend oseltamivir for routine treatment
82 of uncomplicated influenza infections [16, 17]. While the data from several of the early clinical trials

83 are now available, these data are given as pdf scans of redacted reports and not the actual raw data
84 which precludes more detailed analysis by other investigators. Moreover, as far as we are aware
85 data from most recent clinical trials of other anti-influenza drugs such as baloxavir are not publicly
86 available [18].

87 Having properly formatted, digitized data from clinical trials could be extremely useful to un-
88 derstanding the impact of the drug treatment on influenza virus dynamics in humans. Furthermore,
89 such shedding data could be useful to further understand mechanisms that control duration and mag-
90 nitude of viral shedding in humans. For example, kinetics of influenza A virus shedding in several
91 human volunteers has been analyzed with the use of mathematical models [19–21]. Interestingly, one
92 of the earliest modelling studies suggested that the dynamics of influenza A virus shedding in human
93 volunteers can be well described by a so-called target cell limited model in which virus dynamics is
94 only restricted by the availability of targets for virus replication [19]. However, Baccam *et al.* [19]
95 study used data from only a few volunteers that were not treated with drugs; therefore, it remains
96 unclear if the same model can describe more variable data from a large group of infected volunteers,
97 or if other alternative models of viral control may be also consistent with viral shedding patterns
98 [22, 23].

99 In this paper we carefully digitized data on influenza virus shedding in human volunteers from
100 three previously published clinical trials and performed basic analysis of these data. The primary
101 goals of the analysis were to reproduce published results on oseltamivir treatment impact on viral
102 shedding and to provide the community with well curated datasets on viral dynamics that other
103 researchers may utilize further.

104 **Material and methods**

105 **Experimental Design**

106 Three randomized placebo-controlled clinical trials using influenza A virus (H1N1, 1 trial) or influenza
107 B virus (2 trials) were done using volunteers [12, 13]. In short, volunteers were inoculated through the
108 nose with the influenza virus strain of the trial at time zero. Treatment type varies by trial (Figure
109 1 and Table 1). The influenza A trial used a placebo group and a group treated with oseltamivir at
110 daily with 20 mg, 100 mg, 200 mg bid (twice daily), or 200 mg od (once daily). Influenza B study A
111 trial used a placebo group and a group treated daily with oseltamivir at 75 mg or 150 mg. Influenza
112 B study B trial used a placebo group and a group treated daily with 75 mg of oseltamivir. In all
113 three trials treatment began at 24 hours after virus inoculation and nasal washings were taken every
114 12 hours until 96 hours (4 days) after inoculation. At that point nasal washings were taken every 24
115 hours until 216 hours (9 days). The nasal washings were tested for the viral titer (amount of viral
116 shedding in the patient).

117 **Experimental Data**

118 **Data digitization.** Redacted PDF files describing in detail clinical trials have been downloaded in
119 2014 from dryad.org (<https://datadryad.org/resource/doi:10.5061/dryad.77471/2>). Data from three
120 trials involving treatment of volunteers with oseltamivir (Tamiflu) 24 hours after controlled exposure
121 to influenza viruses were chosen for further analysis: study on infection with influenza A virus (“Flu
122 A study”, report PV15616), and two studies on infection with influenza B virus (“Flu B study A”,




Figure 1: Schematic representation of experimental design and basic characteristics of viral shedding data. A) volunteers were inoculated with influenza A or B virus at time zero, and treatment with oseltamivir (or placebo) started at 24 hours [12, 13]. Nasal washing to measure viral titers were taken every 12 hours starting at 24 hours until 96 hours, and every 24 hours thereafter until 216 hours (9 days). B) Basic parameters estimated from kinetics of shedding including the duration of infection (DOI or T ; $T = 8$ days in the cartoon), total viral shedding (area under the curve, AUC), viral growth rate (r), and viral decline rate (δ). Area under the curve (AUC) was calculated for viral concentration on the linear scale and then \log_{10} -transformed (see eqn. (1)).

123 report NP15717 and “Flu B study B”, report NP15827) [12, 13]. The data in the original PDF files
 124 were given in day:hour:min time units for times of virus inoculation or when measurements of viral
 125 shedding were taken. Viral titers were measured in tissue-culture infectious doses per ml (TCID₅₀/ml)
 126 and are given in \log_{10} units. The data were digitized by KLH into a spreadsheet format with time
 127 given in minutes or days since infection. Accuracy of digitization was confirmed by checking the
 128 correspondence between pdf files by another student for a set of randomly chosen volunteers.

Study	LOD TCID/ml	# of all volunteers	# of placebo volunteers: Included[Excluded]	# of treated volunteers: Included[Excluded]					
				20mg	75mg bid	100mg	150mg bid	200mg bid	200mg od
FluA	0	80	12[4]	13[3]	-	13[3]	-	15[1]	13[3]
FluB study A	0	60	13[7]	-	10[10]	-	10[10]	-	-
FluB study B	0	117	27[12]	-	49[29]	-	-	-	-

Table 1: Details of the datasets analyzed in the paper. Some volunteers were excluded from the analysis because the volunteer’s viral titers never exceeded the limit of detection, and thus were interpreted as uninfected. Impact of the limit of detection (LOD) on the number of patients selected as “infected” for every study is evaluated in Table 2. Data are from previously published clinical trials [12, 13]. Other used abbreviations: bid: twice daily, od: once daily.

129 **Defining uninfected volunteers.** Not all virus-exposed volunteers shed the virus after virus
 130 inoculation. Volunteers with no viral titer at any point during the trial were excluded from the data
 131 analysis (see (Table 1 and Figures S1-S8 for the number and the lists of excluded volunteers)).

132 **Calculating start and stop of shedding.** To calculate the kinetics at which volunteers started
 133 virus shedding in a given cohort (e.g., placebo-treated individuals in Flu A study) we did the following.
 134 First, for each volunteer we converted the shedding data into 0 or 1 with 0 values being assigned for
 135 times when viral shedding was at or below the LOD and 1 values assigned for all times when viral
 136 shedding exceeded LOD or the time was later than the first time point of the positive viral shedding

137 event. Then we used equally spaced time points (0, 0.5, 1, 1.5, etc. days) and we counted the number
138 of 0 or 1 for all volunteers in the cohort. The resulting data are given as the number of volunteers
139 that started shedding the virus at time $t = 0, 0.5, 1 \dots$ days after the virus inoculation. Similarly, to
140 calculate the time by which volunteers stop shedding we similarly converted viral shedding data to 0
141 or 1 but starting counting time in reverse, starting with the latest time point going backwards. We
142 then similarly calculated the number of individuals in the cohort that are still shedding the virus by
143 time t where t is from sequence 0, 0.5, 1, 1.5, etc. days point infection. The resulting data are given
144 as the number of volunteers that were still shedding the virus at time $t = 0, 0.5, 1 \dots$ days after the
145 virus inoculation. Generated data for each of the clinical trials are provided as supplement.

146 **Median data from published studies.** To compare median shedding curves calculated in our
147 datasets with published values we digitized data for influenza A virus shedding (from Figure 3 in
148 Hayden *et al.* [12]) or influenza B virus shedding (Flu B study B from Figure 2 in Hayden *et al.* [13]).
149 Data were digitized using Engauge Digitizer and are available as supplement to this paper.

150 Statistical Analysis

151 **Duration of infection (DOI).** Duration of infection was defined as the last time point at which
152 shedding was above the limit of detection.

153 **Area under the curve (AUC).** To calculate AUC we converted viral titers which were given
154 in \log_{10} units to the linear scale and then calculated AUC using trapezoid integration method:

$$\text{AUC} = \log_{10} \left(\sum_{i=1}^{n-1} (t_{i+1} - t_i) \left[v_i + \frac{v_{i+1} - v_i}{2} \right] \right), \quad (1)$$

155 where t_i is the i^{th} time point of measurement of viral load, $v_i = 10^{V_i}$ where V_i is the viral load in the
156 data, and n is the total number of time points.

157 **Viral shedding increase (r) or decline (δ) rates.** To calculate the exponential increase
158 (r) in the viral shedding we selected shedding data which are above the LOD and up to the peak
159 of shedding. The growth rate was calculated as the slope of linear function fitted to these (\log_{10})
160 viral titer data multiplied by $\ln(10)$ ($r = \text{slope} \times \ln(10)$). In a similar fashion, for calculating the
161 exponential decline rate (δ) in the viral shedding we selected data after the peak of viral shedding
162 (including the peak value) until the last shedding value above the LOD. The early growth rate was
163 calculated using the last measurement at the LOD and all measurements above the LOD including
164 before the maximum viral titer measurement. In a similar fashion, the late decline rates included
165 all points after the maximum viral titer that were above the LOD and the first measurement at the
166 LOD.

167 **Mathematical modeling of viral shedding start/end.** To quantify the rates at which vol-
168 unteers start or stop shedding we used a novel mathematical model. In the model we assume that
169 the population of shedders may consist of two sub-populations with fraction f and $1 - f$ and each
170 population either start or stop shedding at rates s_1 and s_2 respectively. We assume that progression
171 of a volunteer from “non-shedding” to “shedding” state occurs as a movement via k subcompartments
172 at a rate s_1 or s_2 [24]. Then the probability that a volunteer starts shedding the virus at time t is
173 given by an incomplete gamma function $\Gamma(k, t) = \int_t^\infty x^{k-1} e^{-x} dx$ where k is the shape parameter of
174 the distribution and $\Gamma(k) = \Gamma(k, 0) = (k - 1)!$. Assuming that shedding starts (or stops) after a delay
175 τ the proportion of volunteers that start shedding by time t after infection is given by the formula

$$S_{start}(t) = \begin{cases} 1 - f\Gamma(k, s_1(t - \tau))/\Gamma(k) - (1 - f)\Gamma(k, s_2(t - \tau))/\Gamma(k), & \text{if } t > \tau, \\ 0, & \text{otherwise.} \end{cases} \quad (2)$$

176 To describe how volunteers stop shedding the virus at time t after infection we used formula

$$S_{stop}(t) = 1 - S_{start}(t) \quad (3)$$

177 with $S_{start}(t)$ being defined in eqn. (2). To characterize the speed at which volunteers start or stop
178 shedding we used average time defined as $T_i = k/s_i$. To fit the models to experimental data we used
179 a likelihood approach that had been used previously to describe viral escape from T cell immunity
180 [25, 26]. Specifically, to describe the fraction of volunteers that start shedding the virus the negative
181 log-likelihood of the data given the model is

$$\mathcal{L}(data|model) = -\log L = -\sum_{t=1}^n \left[n_t \log S_{start}(t) + (N - n_t) \log(1 - S_{start}(t)) \right], \quad (4)$$

182 where n_t is the number of volunteers who have started virus shedding by time t , N is the total
183 number of volunteers in the cohort, S_{start} is given in eqn. (2), and we ignored the constant terms
184 which are irrelevant when maximizing likelihood. Alternative models in this analysis also included one
185 population model ($f = 1$ and $s_2 = 0$), no delay ($\tau = 0$), or exponentially distributed shedding times
186 ($k = 1$). Confidence intervals for the model parameters were estimated using bootstrap approach
187 [27]. For each cohort we resampled volunteers in the cohort with replacement and then followed the
188 same procedure outlined above and calculated the number of individuals that start (or stop) shedding
189 by particular time after the virus inoculation. The model was then fit to 1,000 of such resampled
190 datasets for each cohort, and 95% confidence intervals were calculated from the distributions of
191 estimated parameters.

192 **Tests.** All major analyses were done in R (version 3.1) or Mathematica 11.3. Fitting the mathe-
193 matical models to data was done in Mathematica 11.3. Statistical comparisons for various parameters
194 estimated for placebo and treated volunteers were done using nonparameteric unpaired Wilcoxon test
195 (identical to Mann-Whitney test). Nested models were compared using likelihood ratio test (LRT).
196 To compare similarity in kinetics of start or end of virus shedding between placebo- and drug-treated
197 volunteers we fitted the data from two cohorts with either individual parameters per cohort/dataset or
198 with the same parameters for both cohorts/datasets. We then used likelihood ratio test to determine
199 if parameters for virus shedding start/end were different between the two cohorts/datasets.

200 Results

201 Defining limit of detection

202 In clinical trials testing efficacy of oseltamivir, healthy volunteers were inoculated with a defined dose
203 of the influenza A or B viruses (see Materials and methods for more detail and [12, 13]). Interestingly,
204 many volunteers did not shed any detectable virus for the whole duration of the clinical trial (17.5% in
205 flu A clinical trial, 45% in flu B study A and 35% in flu B study B, Figures S1–S9). These individuals
206 were excluded from further analyses on the kinetics of viral shedding. While most other volunteers
207 showed consistent and high viral shedding, some volunteers showed detectable (above zero) shedding

208 only at one time point. It was unclear from the study descriptions whether such individuals should
 209 be counted as infected or if such viral blips are false positives. We investigated how changing the
 210 limit of detection (LOD) may impact the number of volunteers classified as infected for these clinical
 211 trials.

Influenza A LOD	# Placebo Excluded	# Placebo Included	# Treated Excluded	# Treated Included	P-value (1-tailed/2-tailed)
0.0	0	12	0	54	1.0/1.0
0.84	1	11	6	48	0.63/1.0
1.76	2	10	13	41	0.45/0.72
2.76	4	8	24	30	0.36/0.54
Influenza B Study A LOD	# Placebo Excluded	# Placebo Included	# Treated Excluded	# Treated Included	P-value (1-tailed/2-tailed)
0.0	0	13	0	21	1.0/1.0
0.50	1	12	3	18	0.50/1.0
1.0	4	9	6	15	0.59/1.0
Influenza B Study B LOD	# Placebo Excluded	# Placebo Included	# Treated Excluded	# Treated Included	P-value (1-tailed/2-tailed)
0.0	0	27	0	49	1.0/1.0
0.42	0	27	0	27	1.0/1.0
0.84	3	24	9	40	0.32/0.52
1.50	4	23	21	28	0.011/0.021

Table 2: Impact of the limit of detection (LOD) on the number of volunteers defined as infected or uninfected in three analyzed clinical trials. We used different values for LOD to define which individuals became infected following exposure to influenza viruses. Individual was defined infected when viral shedding was above LOD at least at one time point during the trial. The number of included/excluded individuals is shown in individual columns. We also performed a 2x2 contingency table test by comparing the fraction of infected individuals in placebo vs. treated groups, and the the p-values from the tests (both 1 tailed and 2 tailed) are shown.

212 We reasoned that because treatment started 24 hours after infection and replication cycle of
 213 influenza viruses is relatively short (< 24 h [28, 29]), oseltamivir should not impact the probability
 214 of a person to be infected [30]; therefore, by changing the LOD the difference between percent of
 215 infected in placebo- or drug-treated groups can be evaluated using two-by-two contingency tables
 216 (Table 2). The basic idea was to vary the LOD to several values that viral titers take in a given
 217 trial and see at which values the frequency of volunteers that shed the virus at any time point (i.e.,
 218 have viral titers above the threshold value) is the same between placebo and treatment groups. We
 219 tried several different values of the LOD and only in 3rd trial (Flu B study B) increasing the LOD to
 220 $1.5 \log_{10}$ TCID₅₀/ml impacted significantly the frequency of infection between placebo and treated
 221 volunteers. Because increasing LOD reduced the number of volunteers shedding the virus above LOD
 222 (Table 2), we converged to use LOD = 0 in our further calculations; some results were also checked
 223 assuming other values for LOD (see below). Importantly, using LOD = 0 we could match the median
 224 virus shedding titers for placebo- and drug-treated volunteers in Flu A study suggesting that this
 225 was the likely LOD in that study (see below).

226 **Impact of oseltamivir treatment on overall shedding pattern in human** 227 **volunteers**

228 Having defined the LOD for the data we then compared how accurately median shedding curves
 229 represent virus shedding patterns in individual volunteers (Figure 2; see Materials and Methods for
 230 how median shedding curves were calculated). Interestingly, for flu A-infected volunteers there was
 231 a reasonable correspondance between median shedding curves and shedding for individual placebo-

232 and drug-treated volunteers; however, there are clearly examples of individuals that did not follow
 233 the median pattern (Figure 2A&D). The match between median shedding and shedding in individual
 234 volunteers was poor for both studies with influenza B virus; particularly, median curves poorly
 235 represented individuals that continued to shed the virus in both placebo- and drug-treated controls
 236 (e.g., Figure 2B&E) illustrating a severe limitation of presenting the data by median shedding alone.




Figure 2: Commonly reported median viral shedding curves do not accurately represent shedding in many patients. We analyzed experimental data from 3 clinical trials of volunteers infected with influenza A (panels A&D) or influenza B (panels B-C&E-F) viruses and treated 24 hours after viral exposure with placebo (panels A-C) or oseltamivir (panels D-F); start of treatment is indicated by the vertical dashed lines. Viral shedding in individual volunteers is shown by gray lines and median viral titers are shown by thick red lines with markers. For median viral titers we also calculated the duration of infection (T), the rate of viral growth (r) and viral decay (δ), and the total area under the curve (AUC, eqn. (1)). Details of the experiments and basic viral characteristics calculated are given in [12, 13, see Figure 1]. The limit of detection is represented by the horizontal thin dashed line; the detection limit was 0 log₁₀ TCID₅₀/ml for all data. Viral shedding curves in individual volunteers are shown in Supplement (Figures S1–S9).

237 For our median shedding curves we calculated several basic parameters characterizing virus dy-
 238 namics such as the duration of infection (T), the overall viral shedding (defined as area under the
 239 curve, AUC), the virus growth rate prior to peak r , and the virus decline rate after the peak δ .
 240 Treatment impacted these parameters for the median shedding curves differently. In particular,
 241 oseltamivir treatment reduced the median duration of infection from 5 to 3 days and reduced the overall
 242 viral shedding over 10 fold (from 4.2 to 2.9) in flu A clinical trial as judged by the median shedding
 243 curves (Figure 2A&D). Also as judged by the median shedding curves, in influenza A virus-infected
 244 individuals treatment reduced the rate of viral growth and increased the rate of viral clearance
 245 after the peak (Figure 2A&D). In contrast, in flu B study A drug treatment did not reduce the overall
 246 median shedding and resulted in slower viral clearance after the peak (Figure 2B&E). Finally, in flu
 247 B study B, treatment did not appear to have an impact on viral growth or decline rates of the median
 248 shedding data but did result in shorter infection and less overall virus being shed (Figure 2C&F).

249 Given that median viral shedding curves did not necessarily well represent shedding observed
 250 in individual volunteers, impact of the treatment on median shedding curves may be misleading.
 251 Therefore, we performed an alternative analysis in which we calculated the same parameters (T ,

252 AUC, r , and δ) for individual patients (Figure 3). It is important to emphasize that it was not
253 possible to calculate virus growth and decay rates for all volunteers because this procedure required
254 at least two measurements to be above LOD during viral increase or decline phases which was not
255 available in all volunteers. Interestingly, we found that oseltamivir treatment did reduce the overall
256 duration of infection and the total shedding in flu A study and flu B study B, but there was no
257 difference in these two parameters between placebo- and drug-treated individuals in flu B study A
258 (Figure 3).




Figure 3: Impact of oseltamivir treatment on the duration of infection and the overall viral shedding depends on the study. For every volunteer in 3 clinical trials we calculated the duration of infection (panels A-C) or the overall shedding defined as AUC (see Materials and methods for detail) for Flu A (A&D), Flu B study A (B&E), or Flu B study B (C&F) data. Horizontal lines indicate median values. The number of volunteers, n , analyzed in each of the trial and tests is shown on the x -axis of each graph. Comparisons between groups done using Mann-Whitney test and p values from the test are shown on individual panels.

259 Our analysis of the virus kinetics defined by the virus shedding growth rate to the peak and
260 virus decline rate after the peak based on median virus shedding curves suggested that oseltamivir
261 influences these rates albeit in trial-dependent manner [22, Figure 2]. Specifically, we found that
262 oseltamivir increases the rate of virus decline after the peak in the median data in flu A clinical trial
263 [22]. In contrast, analysis of individual shedding curves did not reveal impact of the olsetamivir on
264 either viral growth or viral decline rates (Figure 4).

265 In calculating virus growth and decay rates for individual volunteers we only used values that
266 were above the LOD; therefore, this approach is likely to capture the average rates of virus shedding
267 change. We wondered if drug treatment may impact the very early rate of virus shedding increase
268 (or the very late virus shedding decline). Therefore, we also calculated two additional rates - the
269 rate at which virus shedding increases early during the infection (by using the data that included
270 one measurement at the LOD prior to detectable virus but before the viral peak) and the late rate
271 of virus decline (by using the data after the peak shedding until the first measurement at LOD; see
272 Materials and Methods for more detail). Interestingly, there was no evidence that the rate at which
273 virus shedding increased early was changing over time either in placebo- or drug-treated volunteers
274 (Figure S11). In contrast, the rate at which virus shedding was declining was slowing down with
275 time since infection for some data (Figure S12).




Figure 4: Oseltamivir treatment does not influence median viral growth and decline rates in individual volunteers. For the data from 3 clinical studies for every volunteer we calculated the rate at which viral shedding increased (A-C) or declined (D-F) with time for Flu A (A&D), Flu B study A (B&E), and Flu B study B (C&F) data. Only volunteers with the data above limit of detection (LOD) and at least two data points for virus increase to the peak or virus decline after the peak were included. Horizontal lines denote median values. The number of volunteers, n , analyzed in each of the trial and tests is shown on the x -axis of each graph. Comparisons between groups done using Mann-Whitney test and p values from the test are shown on individual panels.

276 Both flu A study and flu B study A tested the impact of different drug dosing on viral control
277 (see Materials and Methods). Additional analysis showed that interestingly the oseltamivir's dose
278 had no measurable impact on the basic parameters for virus shedding kinetics which further justifies
279 considering drug-treated volunteers as a single group (Figures S13 and S14).

280 Matching median virus shedding curves with published studies

281 Original reports of the analyzed clinical trials included median viral shedding curves for the influenza
282 A trial [12] and the influenza B study B trial [13]. We therefore investigated whether median viral
283 shedding curves from our digitized data would accurately match published median viral curves. In
284 our analyses we found that the assumed LOD influenced the resulting median shedding curve, and
285 interestingly, by assuming $LOD = 0$ we found a nearly perfect match between median viral shedding
286 in our data and published values for flu A clinical trial (Figure 5A&C). For the full match the median
287 shedding data found in our analysis had to be shifted by 12h, though. In contrast, we could not fully
288 match median viral shedding curves for flu B study B clinical trial for several values of the LOD
289 (results not shown). Furthermore, even to provide a reasonable match with $LOD = 0$ the median
290 shedding curve in our analysis had to be shifted by 24 hours (Figure 5B&D). We could not identify
291 the reasons for this discrepancy. This result further suggests the need to publish raw data from such
292 clinical trials so that some of the results can be independently verified.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure 5: Previously published median virus shedding data could be reproduced for one but not another clinical trial. We compared median shedding data published previously for clinical trial with flu A [12] or flu B study B [13] with median shedding calculated from the raw trial data. The best match was found by assuming $LOD = 0$. For every panel we also list the number of volunteers used to calculate the median titers. The best match was obtained by shifting the published median shedding curves by 12 h (A&C) or by 24 hours (B&D).

293 Oseltamivir treatment impacts the overall dynamics of start and end of 294 shedding

295 Viral shedding dynamics in individual volunteers is relatively asynchronous – the time when individ-
296 uals start or stop viral shedding (i.e., with viral shedding being above the LOD) varied. We therefore
297 investigated if the rate at which volunteers started or stopped shedding was dependent on the virus
298 type and, more importantly, on the oseltamivir treatment. We developed a novel mathematical
299 model predicting start (or end) of shedding in the cohort of patients, based on a mixture of two
300 gamma distributions, and estimated the model parameters by fitting a series of nested models to the
301 data. Specifically, placebo- or drug-treated volunteers were followed as a cohort and the fraction of
302 volunteers that started virus shedding by time t since infection (Figure 6A,C,E) or stopped shedding
303 by time t (Figure 6B,D,F) was calculated. The models were fitted using a likelihood method and the
304 best fit model was determined using likelihood ratio test (see Materials and methods for more detail
305 and Figure 6).

306 Several interesting results emerged. The kinetics of start of viral shedding was similar for both
307 influenza virus types with half of individuals starting shedding within 1-2 days since infection. The
308 best fit model describing shedding kinetics varied with the study and was dependent on the treatment
309 type; interestingly, oseltamivir-treated volunteers infected with influenza A virus started shedding
310 the virus with a different kinetics as compared to controls (LRT: $p = 0.046$, Figure 6A and Table
311 3). However, in other two studies start of shedding kinetics was similar between placebo- and drug-
312 treated volunteers (Figure 6 and Table 3).

313 The kinetics at which volunteers stopped shedding was even more intriguing. Only for flu B study




Figure 6: Oseltamivir treatment influences start and end of influenza virus shedding. We calculated the cumulative fraction of volunteers that start (A, C, E) or stop (B, D, F) shedding following infection with influenza A (A-B) or influenza B (C-E) viruses. Data are shown by markers for placebo or treated volunteers and in parentheses we show the numbers of volunteers in each cohort. We fitted a general mathematical model (given in eqn. (2) or eqn. (3)) to these data and the predictions of the best fit models are shown by lines. For every fit the minimal number of fitted parameters was selected using likelihood ratio test. Best fit parameters are shown in Table 3. In panels, $T = k/s_i$ is the average shedding time and τ is the delay in shedding (see eqn. (2) for parameter definition). There was a moderate difference in the kinetics of start of shedding in Flu A study between placebo- and drug-treated volunteers ($p = 0.046$), but no difference was observed in start of virus shedding two studies with flu B. In FluA study and FluB study B the kinetics of stop of shedding was different between placebo and treated volunteers as judged by the likelihood ratio test ($p < 0.001$ for both comparisons); for FluB study A and study B there was not difference in kinetics of end of viral shedding ($p > 0.2$ for two comparisons). Error bars were estimated for binomial proportions using Jefferey's intervals [31].

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Study	Treatment	Shedding	s_1 , 1/day	s_2 , 1/day	f	k	τ , day
Flu A	placebo	start	1.16 (0.78-34.64)	0	1	1	0.5 (0.5-0.96)
Flu A	treated	start	2.15 (1.62-3.69)	0	1	1	0.69 (0.52-0.83)
Flu A	placebo	stop	3.35 (1.68-15.27)	0	1	16.79 (8.61-84.87)	0
Flu A	treated	stop	3.27 (0.94-4.08)	6.72 (2.47-8.55)	0.2 (0.07-0.61)	19.36 (7.66-23.64)	0
Flu B study A	placebo	start	2.48 (0.98-26.85)	0	1	2.03 (0.2-48.42)	1.31 (0-2.0)
Flu B study A	treated	start	5.68 (1.85-46.24)	0	1	4.39 (0.44-74.43)	1.46 (0-1.99)
Flu B study A	placebo	stop	0.54 (0.2-0.96)	0	1	3.63 (1.93-5.72)	0
Flu B study A	treated	stop	6.48 (1.87-13.67)	15.44 (5.29-36.51)	0.43 (0.2-0.64)	52.75 (18.61-124.6)	0
Flu B study B	placebo	start	1.87 (1.35-3.75)	0	1	1	1.21 (1.0-1.39)
Flu B study B	treated	start	4.91 (3.30-14.37)	0	1	3.9 (2.15-32.62)	0.92 (0.0-1.0)
Flu B study B	placebo	stop	0.66 (0.30-1.02)	0	1	4.12 (2.18-6.47)	0
Flu B study B	treated	stop	4.72 (3.07-8.10)	10.73 (7.11-21.54)	0.23 (0.12-0.36)	31.3 (20.32-57.77)	0

Table 3: Parameters providing the best fit of the model (given by eqn. (2) or eqn. (3)) to the data on start or end of shedding by volunteers in three clinical trials. Data and model fits are shown in Figure 6. To generate the survival curves we used $LOD = 0$. The models were fitted to the data from 3 clinical trials (Flu A, Flu B study A, and Flu B study B), for placebo or oseltamivir-treated volunteers, and for start or end of shedding. Each dataset is thus named to include these details. When values are given as integers (e.g., $s_2 = 0$, $f = 1$, $k = 1$, or $\tau = 0$), these parameters were fixed to the noted values in model fits to data. Allowing these parameters to be fit did not improve the quality of the model fit of the data based on likelihood ratio test (results not shown). Confidence intervals in estimated parameters (shown in parentheses) were estimated by resampling data for individual volunteers 1,000 times with replacement.

314 A we found no differences in the kinetics of viral shedding end between placebo- and oseltamivir-
 315 treated volunteers (Figure 6D); however, the model fits predicted that in about 43% of drug-treated
 316 individuals the loss of virus shedding proceeded similarly to that of placebo-treated volunteers (given
 317 by parameter f in Table 3). Indeed, average time to stop shedding was $3.63/0.54 = 6.7$ days and
 318 $52.75/6.48 = 8.1$ days for placebo- and drug-treated volunteers, respectively, suggesting that the
 319 drug may have failed in preventing virus replication in many individuals in this trial. There were
 320 statistically significant differences in the kinetics of loss of viral shedding between placebo- and drug-
 321 treated volunteers in flu A study and flu B study B (Figure 6B&F and Table 3). In these trials, about
 322 20% of drug-treated volunteers stopped shedding the virus with similar timing to that of placebo-
 323 treated individuals (Table 3). Thus, our novel analysis identified variable impact of the oseltamivir
 324 treatment on the kinetics at which virus shedding starts or ends in human volunteers.

325 Discussion

326 One of the great advantages of testing efficacy of vaccines or drugs against influenza viruses is the
 327 ability to perform controlled human challenge studies in which volunteers (placebo and drug-treated
 328 or vaccinated) are exposed to well defined dose and type of the virus [32, 33]. However, results of
 329 such important trials in general have been presented in succinct manner; e.g., typically median virus
 330 shedding curves are presented and public access to data on influenza virus dynamics in individual
 331 volunteers is not provided [12, 13, 18]). In our personal experience researchers that do have access
 332 to such raw data have not been willing to share them. In this study we took advantage of now
 333 publicly available reports from three clinical studies testing efficacy of oseltamivir given 24 hours
 334 after exposure volunteers to influenza A or B viruses. We have converted scanned pdf pages into
 335 spreadsheet format data that can be analyzed further and make it a resource for the community. We
 336 have also performed several basic analyses of these data.

337 We found that some of the previously published results could be reproduced, i.e., oseltamivir
 338 treated did reduce the duration of viral shedding and the overall viral shedding in 2 out of 3 trials

339 (Figure 3); however, a closer inspection of the data revealed that many treated volunteers continued
340 shedding the virus suggesting treatment failure. Indeed, by looking at the kinetics at which volunteers
341 stop shedding we found that between 20-40% of treated volunteers continued shedding similarly as
342 placebo-treated controls further suggesting treatment failure (Figure 6). Our mathematical model-
343 driven analysis also suggested that treatment with oseltamivir may in fact speed up start of shedding,
344 most noticeable in flu A clinical trial (Figure 6A). While mechanisms of this process are unclear –
345 we could not find information on the volunteers that shed the virus early – further studies may need
346 to investigate this possibility further.

347 We could only partially reproduce previously published median shedding curves, specifically for flu
348 A trial but only after shifting the published median shedding curves to allow for a nearly perfect match
349 (Figure 5A&C). Why it was not possible for flu B study B remains unclear. It is also interesting
350 to note that while analysis of the median shedding curves in flu A study suggested a faster viral
351 clearance in oseltamivir-treated volunteers [22], virus clearance rates were similar when evaluated for
352 individual volunteers (Figure 4). Given that oseltamivir treatment also did not impact the early virus
353 growth rate this may suggest that virus shedding is controlled mainly by innate mechanisms (e.g.,
354 target cell limitation, [19, 22]). Further studies should investigate in more detail whether alternative
355 models for virus control are consistent with shedding data for individual volunteers infected with
356 influenza A or B viruses [22, 34].

357 Our work has some limitations. Because original virus shedding data were in PDF format we
358 cannot exclude the possibility that there have been errors in our translation from the given days/times
359 since infection to digital format. We attempted to minimize such errors by having another investigator
360 to check correctness of the digitization. We could not determine why some volunteers responded well
361 to the drug and improved clearance of the virus while others did not. It was not possible to find
362 clear answers in the clinical trial notebooks. Our analysis of virus growth and decay rates depended
363 strongly on the measured values (above LOD), and more frequent measurements of viral shedding
364 are likely to provide a more accurate estimates of these rates.

365 Our work generates several recommendations that should be implemented for clinical trial data
366 on human challenge studies with influenza viruses. We believe that original shedding data should be
367 shared following publication of the work. The data can be anonymized and redacted if needed, but
368 the critical numeric data must be provided in the proper digital format (e.g., spreadsheets or similar).
369 For example, recent clinical trial data for baloxavir have not been made available [18]. Authors that
370 provide re-analysis of the data from clinical trials should also attempt to provide public access to such
371 data. Data sharing is likely to improve science reproducibility which is likely to ultimately benefit
372 influenza virus-infected patients.

373 **Author contributions**

374 KLH digitized the data from original publications into spreadsheet format. KLH and VVG have
375 analyzed the data and wrote the manuscript.

376 **Data sources**

377 Data on virus shedding from the three clinical studies are available as supplement to this paper.

378 Code sources

379 Mathematica codes used for data analysis are available as supplement to this paper.

380 Acknowledgments

381 We would like to thank our research community for pressuring Roche to release primary research
382 data from oseltamivir clinical trials. We also thank several students in the GanusovLab for helping
383 with some primary analyses and checks of the digitized data. This work was in part supported by
384 the NIH grant (R01 GM118553) to VVG.

385 References

- 386 1. Petrova, V. N. & Russell, C. A. 2018 The evolution of seasonal influenza viruses. *Nature reviews.*
387 *Microbiology*, **16**, 47–60. doi:10.1038/nrmicro.2017.118.
- 388 2. Moghadami, M. 2017 A narrative review of influenza: A seasonal and pandemic disease. *Iranian*
389 *journal of medical sciences*, **42**, 2–13.
- 390 3. Brankston, G., Gitterman, L., Hirji, Z., Lemieux, C. & Gardam, M. 2007 Transmission of in-
391 fluenza a in human beings. *The Lancet. Infectious diseases*, **7**, 257–265. doi:10.1016/S1473-
392 3099(07)70029-4.
- 393 4. Paget, J., Spreeuwenberg, P., Charu, V., Taylor, R. J., Iuliano, A. D., Bresee, J., Simonsen, L.,
394 Viboud, C., Network, G. S. I.-a. M. C. *et al.* 2019 Global mortality associated with seasonal
395 influenza epidemics: New burden estimates and predictors from the glamor project. *Journal of*
396 *global health*, **9**, 020 421. doi:10.7189/jogh.09.020421.
- 397 5. Kim, H., Webster, R. G. & Webby, R. J. 2018 Influenza virus: Dealing with a drifting and shifting
398 pathogen. *Viral immunology*, **31**, 174–183. doi:10.1089/vim.2017.0141.
- 399 6. Dhakal, S. & Klein, S. L. 2019 Host factors impact vaccine efficacy: Implications for seasonal
400 and universal influenza vaccine programs. *Journal of virology*, **93**. doi:10.1128/JVI.00797-19.
- 401 7. Ang, L. W., Tien, W. S., Lin, R. T.-P., Cui, L., Cutter, J., James, L. & Goh, K. T. 2016
402 Characterization of influenza activity based on virological surveillance of influenza-like illness in
403 tropical singapore, 2010-2014. *Journal of medical virology*, **88**, 2069–2077. doi:10.1002/jmv.24566.
- 404 8. Mifsud, E. J., Hayden, F. G. & Hurt, A. C. 2019 Antivirals targeting the polymerase complex of
405 influenza viruses. *Antiviral research*, **169**, 104 545. doi:10.1016/j.antiviral.2019.104545.
- 406 9. Yang, J., Huang, Y. & Liu, S. 2019 Investigational antiviral therapies for the treat-
407 ment of influenza. *Expert opinion on investigational drugs*, **28**, 481–488. doi:
408 10.1080/13543784.2019.1606210.
- 409 10. Principi, N., Camilloni, B., Alunno, A., Polinori, I., Argentiero, A. & Esposito, S. 2019 Drugs
410 for influenza treatment: Is there significant news? *Frontiers in medicine*, **6**, 109. doi:
411 10.3389/fmed.2019.00109.

- 412 11. Lampejo, T. 2020 Influenza and antiviral resistance: an overview. *European journal of clinical*
413 *microbiology and infectious diseases : official publication of the European Society of Clinical*
414 *Microbiology*, **39**, 1201–1208. doi:10.1007/s10096-020-03840-9.
- 415 12. Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills,
416 R. G., Ward, P. *et al.* 1999 Use of the oral neuraminidase inhibitor oseltamivir in experimental
417 human influenza: randomized controlled trials for prevention and treatment. *JAMA*, **282**(13),
418 1240–1246.
- 419 13. Hayden, F. G., Jennings, L., Robson, R., Schiff, G., Jackson, H., Rana, B., McClelland, G.,
420 Ipe, D., Roberts, N. *et al.* 2000 Oral oseltamivir in human experimental influenza b infection.
421 *Antiviral therapy*, **5**, 205–213.
- 422 14. Jefferson, T., Demicheli, V., Deeks, J. & Rivetti, D. 2000 Neuraminidase inhibitors for prevent-
423 ing and treating influenza in healthy adults. *The Cochrane database of systematic reviews*, p.
424 CD001265. doi:10.1002/14651858.CD001265.
- 425 15. Reddy, D. 2010 Responding to pandemic (h1n1) 2009 influenza: the role of oseltamivir. *The*
426 *Journal of antimicrobial chemotherapy*, **65 Suppl 2**, ii35–ii40. doi:10.1093/jac/dkq014.
- 427 16. Jefferson, T. O., Demicheli, V., Di Pietrantonj, C., Jones, M. & Rivetti, D. 2006 Neuraminidase
428 inhibitors for preventing and treating influenza in healthy adults. *The Cochrane database of*
429 *systematic reviews*, p. CD001265. doi:10.1002/14651858.CD001265.pub2.
- 430 17. Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer,
431 E. A., Onakpoya, I., Mahtani, K. R. *et al.* 2014 Neuraminidase inhibitors for preventing and
432 treating influenza in healthy adults and children. *The Cochrane database of systematic reviews*,
433 p. CD008965. doi:10.1002/14651858.CD008965.pub4.
- 434 18. Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., Ishida, T.,
435 Sekino, H., Yamada, K. *et al.* 2018 Baloxavir marboxil for uncomplicated influenza in adults and
436 adolescents. *The New England journal of medicine*, **379**, 913–923. doi:10.1056/NEJMoa1716197.
- 437 19. Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. 2006 Kinetics of
438 influenza a virus infection in humans. *Journal of virology*, **80**, 7590–7599. doi:10.1128/JVI.01623-
439 05.
- 440 20. Canini, L., Conway, J. M., Perelson, A. S. & Carrat, F. 2014 Impact of different oseltamivir regi-
441 mens on treating influenza a virus infection and resistance emergence: insights from a modelling
442 study. *PLoS computational biology*, **10**, e1003568. doi:10.1371/journal.pcbi.1003568.
- 443 21. Canini, L., Woolhouse, M. E. J., Maines, T. R. & Carrat, F. 2016 Heterogeneous shedding of
444 influenza by human subjects and its implications for epidemiology and control. *Scientific reports*,
445 **6**, 38749. doi:10.1038/srep38749.
- 446 22. Le, D. 2014 Mathematical and experimental studies of immune response to viral infection (yellow
447 fever, smallpox, influenza). Honor's thesis, University of Tennessee.
- 448 23. Ganusov, V. V. 2016 Strong Inference in Mathematical Modeling: A Method for Robust Science
449 in the Twenty-First Century. *Front Microbiol*, **7**, 1131. doi:10.3389/fmicb.2016.01131.

- 450 24. Ganusov, V. V. & Tomura, M. Experimental and mathematical approaches to quantify recir-
451 culation kinetics of lymphocytes. In *Mathematical, Computational and Experimental T Cell*
452 *Immunology* (ed. G. L. C. MOLINA-PARIS). Springer Nature Switzerland.
- 453 25. Ganusov, V. V., Neher, R. A. & Perelson, A. S. 2013 Modeling HIV escape from cytotoxic T
454 lymphocyte responses. *J Stat Mech*, **2013**(01), P01 010.
- 455 26. Ganusov, V. V. 2018 Time intervals in sequence sampling, not data modifications, have a major
456 impact on estimates of HIV escape rates. *Viruses*, **10**. doi:10.3390/v10030099.
- 457 27. Efron, B. & Tibshirani, R. 1993 *An introduction to the bootstrap*. New York: Chapman & Hall.
- 458 28. Frensing, T., Kupke, S. Y., Bachmann, M., Fritzsche, S., Gallo-Ramirez, L. E. & Reichl, U.
459 2016 Influenza virus intracellular replication dynamics, release kinetics, and particle morphology
460 during propagation in mdck cells. *Applied microbiology and biotechnology*, **100**, 7181–7192. doi:
461 10.1007/s00253-016-7542-4.
- 462 29. Laske, T., Bachmann, M., Dostert, M., Karlas, A., Wirth, D., Frensing, T., Meyer, T. F.,
463 Hauser, H. & Reichl, U. 2019 Model-based analysis of influenza a virus replication in genetically
464 engineered cell lines elucidates the impact of host cell factors on key kinetic parameters of virus
465 growth. *PLoS computational biology*, **15**, e1006 944. doi:10.1371/journal.pcbi.1006944.
- 466 30. Cheung, D. H., Tsang, T. K., Fang, V. J., Xu, J., Chan, K.-H., Ip, D. K. M., Peiris, J. S. M.,
467 Leung, G. M. & Cowling, B. J. 2015 Association of oseltamivir treatment with virus shedding,
468 illness, and household transmission of influenza viruses. *The Journal of infectious diseases*, **212**,
469 391–396. doi:10.1093/infdis/jiv058.
- 470 31. Brown, L., Cai, T., DasGupta, A., Agresti, A., Coull, B., Casella, G., Corcoran, C., Mehta, C.,
471 Ghosh, M. *et al.* 2001 Interval estimation for a binomial proportion. *Statistical Science*, **16**(2),
472 101–133.
- 473 32. Memoli, M. J., Czajkowski, L., Reed, S., Athota, R., Bristol, T., Proudfoot, K., Fargis, S., Stein,
474 M., Dunfee, R. L. *et al.* 2015 Validation of the wild-type influenza a human challenge model
475 h1n1pdmist: an a(h1n1)pdm09 dose-finding investigational new drug study. *Clinical Infectious*
476 *Diseases*, **60**, 693–702. doi:10.1093/cid/ciu924.
- 477 33. Balasingam, S. & Wilder-Smith, A. 2016 Randomized controlled trials for influenza drugs and
478 vaccines: a review of controlled human infection studies. *International journal of infectious*
479 *diseases*, **49**, 18–29. doi:10.1016/j.ijid.2016.05.013.
- 480 34. Handel, A., Longini, I. M. & Antia, R. 2010 Towards a quantitative understanding of the within-
481 host dynamics of influenza a infections. *Journal of the Royal Society, Interface*, **7**, 35–47. doi:
482 10.1098/rsif.2009.0067.

483
484
485
486

Impact of oseltamivir treatment on influenza A and B dynamics in human volunteers

Kyla L. Hooker and Vitaly V. Ganusov

Supplemental information




Figure S1: Viral shedding titers for individual volunteers from Flu A study [12]. These are data for placebo-treated volunteers including the volunteer ID, duration of infection, viral growth and viral decline rates, duration of infection, and the total viral sheeting (AUC). Volunteers excluded from the analysis as uninfected have the following IDs: 7, 21, 38, 41.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .




Figure S2: Viral shedding titers for individual volunteers from Flu A study [12] treated with 20mg of oseltamivir. Volunteers excluded from the analysis as uninfected have the following IDs: 56, 68, 79. See Figure S1 for more detail.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S3: Viral shedding titers for individual volunteers from Flu A study [12] treated with 100mg of oseltamivir. Volunteers excluded from the analysis as uninfected have the following IDs: 10, 42, 78. See Figure S1 for more detail.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S4: Viral shedding titers for individual volunteers from Flu A study [12] treated with 200mg of oseltamivir twice daily. Volunteers excluded from the analysis as uninfected have the following IDs: 50. See Figure S1 for more detail.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S5: Viral shedding titers for individual volunteers from Flu A study [12] treated with 200mg of oseltamivir once daily. Volunteers excluded from the analysis as uninfected have the following IDs: 43, 66, 73. See Figure S1 for more detail.




Figure S6: Viral shedding titers for individual volunteers from Flu B study A [13]. These are data for placebo-treated volunteers including the volunteer ID, duration of infection, viral growth and viral decline rates, duration of infection, and the total viral shedding (AUC). Volunteers excluded from the analysis as uninfected have the following IDs: 25, 31, 35, 36, 41, 44, 47.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S7: Viral shedding titers for individual volunteers from Flu B study A [13] treated with 75mg of oseltamivir. Volunteers excluded from the analysis as uninfected have the following IDs: 12, 13, 30, 32, 39, 45, 55, 58, 59, 70. See Figure S6 for more detail.




Figure S8: Viral shedding titers for individual volunteers from Flu B study A [13] treated with 150mg of oseltamivir. Volunteers excluded from the analysis as uninfected have the following IDs: 11, 26, 27, 29, 38, 40, 42, 50, 61, 63. See Figure S6 for more detail.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S9: Viral shedding titers for individual volunteers from Flu B study B [13]. These are data for placebo-treated volunteers including the volunteer ID, duration of infection, viral growth and viral decline rates, duration of infection, and the total viral shedding (AUC). Volunteers excluded from the analysis as uninfected have the following IDs: 8, 17, 204, 303, 308, 314, 319, 324, 346, 49, 58, 67.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S10: Viral shedding titers for individual volunteers from Flu B study A [13] treated with 75mg of oseltamivir. Volunteers excluded from the analysis as uninfected have the following IDs: 2, 10, 11, 18, 208, 214, 215, 305, 310, 311, 325, 326, 328, 330, 335, 338, 345, 347, 351, 48, 54, 57, 60, 61, 64, 66, 72, 74, 75. See Figure S9 for more detail.




Figure S11: Oseltamivir treatment does not result in acceleration of early viral replication rates. We calculated the early virus replication rate by either only including viral shedding data prior to peak that are above the limit of detection (“Average” category) or by including all data points prior to peak including data at the limit of detection (“Early” category). Panels A&D show the Influenza A analyses. Panels B&E show the Influenza B study A analyses. Panels C&F show the Influenza B study B analyses. The small black line in each of the columns of data show the median value for that analysis. The number of volunteers, n , analyzed in each of the trial and tests is shown on the x-axis of each graph. P -values were calculated using the Mann-Whitney test.




Figure S12: Oseltamivir treatment results in a slower viral clearance over time. We calculated the late virus decline rate by either only including viral shedding data after the peak that are above the limit of detection (“Average” category) or by including all data points after the peak including one first data point at the limit of detection (“Late” category). Panels A&D show the Influenza A analyses . Panels B&E show the Influenza B study A analyses. Panels C&F show the Influenza B study B analyses. The small black line in each of the columns of data show the median value for that analysis. The number of volunteers, n , analyzed in each of the trial and tests is shown on the x-axis of each graph. P-values were calculated using the Mann-Whitney test.




Figure S13: Impact of oseltamivir treatment type (dose) on the total viral shedding (AUC, A), duration of infection (B), viral growth (C) and decline (D) rates for individuals in Flu A clinical trial [12]. The differences in estimated parameters between different treatments were not significant (judged by ANOVA). See Figures 3 and 4 for more detail.




Figure S14: Impact of oseltamivir treatment type (dose) on the total viral shedding (AUC, A), duration of infection (B), viral growth (C) and decline (D) rates for individuals in Flu B study A clinical trial [13]. The differences in estimated parameters between different treatments were not significant (judged by ANOVA). See Figures 3 and 4 for more detail.